Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, adaptive, randomized blinded controlled trial of the safety and efficacy of investigational therapeutics for the treatment of COVID-19 in hospitalized adults – version for European Union/United Kingdom sites

Next Previous
Trial Profile

A multicentre, adaptive, randomized blinded controlled trial of the safety and efficacy of investigational therapeutics for the treatment of COVID-19 in hospitalized adults – version for European Union/United Kingdom sites

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2021

Print Profile Download Citation

At a glance

  • Drugs Baricitinib (Primary) ; Remdesivir (Primary)
  • Indications COVID 2019 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ACTT; ACTT I; ACTT-EU/UK; NIAID-ACTT

    • Most Recent Events

    • 12 Jan 2021 Results (n=19) of a sub-study; serum specimens were obtained from hospitalized adults with COVID-19 randomized to Remdesivir or placebo from this trial assessing antibody and cytokine responses published in the Journal of Infectious Diseases
    • 23 Nov 2020 According to a Montefiore Health System and Albert Einstein College of Medicine media release, Dr. Zingman was the principal investigator at Montefiore and Einstein for the ACTT-1 and ACTT-2 National Institutes of Health trials
    • 22 Oct 2020 Additional mortality data from a post-hoc analysis were published in the New England Journal of Medicine, according to a Gilead Sciences media release.

Trial Overview

Outcome

Primary endpoint met - positive

Purpose

This phase III, placebo-controlled trial is designed to evaluate the safety and efficacy of novel therapeutic agents (Remdesivir) in hospitalized adults diagnosed with COVID-19.
The study is comparing different investigational therapeutic agents to a control arm. There will be interim monitoring to introduce new arms and allow early stopping for futility, efficacy, or safety. If one therapy proves to be efficacious, then this treatment may become the control arm for comparison(s) with new experimental treatment(s). Any such change would be accompanied by an updated sample size. Because background standards of supportive care may evolve/improve over time as more is learned about successful management of COVID-19, comparisons of safety and efficacy will be based on data from concurrently randomized subjects. An independent Data and Safety Monitoring Board (DSMB) will actively monitor interim data to make recommendations about early study closure or changes to study arms. To evaluate the clinical efficacy, as assessed by time to recovery, of different investigational therapeutics as compared to the control arm.

Comments

According to a Gilead Sciences media release, the U.S. Food and Drug Administration (FDA) has approved Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization, based on data from ACTT-1 and SIMPLE-Severe studies.

According to a Gilead Sciences media release, the European Commission granted conditional marketing authorization of Veklury on July 3, 2020, based on data from this trial.

The Japanese Ministry of Health, Labour and Welfare (MHLW) granted regulatory approval of Veklury (remdesivir) as a treatment for SARS-CoV-2 infection under an exceptional approval pathway. The exceptional approval was granted due to the COVID-19 pandemic and references the Emergency Use Authorization of remdesivir in the United States. The approval is based on clinical data from the U.S. National Institute of Allergy and Infectious Diseases's global Phase 3 trial, the company's Phase 3 SIMPLE trial in patients with severe manifestations of COVID-19, and available data from company's compassionate use program, including patients in Japan.

The USA Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) use of the investigational antiviral Veklury (remdesivir) to treat all hospitalized patients with COVID-19. The expansion of the scope of the EUA to include hospitalized patients with mild or moderate COVID-19 is supported by the Agency's analysis of additional data from two randomized, controlled clinical trials that included patients with mild or moderate disease (ACTT-1 and Study GS-US-540-5774). The EUA will facilitate broader use of remdesivir to treat hospitalized patients with severe COVID-19 disease, enabling access to remdesivir at additional hospitals across the country. Under the EUA, both 5-day and 10-day treatment durations are suggested, based on the severity of disease.The EUA is temporary and does not take the place of the formal new drug application submission, review and approval process. The EUA allows for the distribution and emergency use of remdesivir only for the treatment of COVID-19, remdesivir remains an investigational drug and has not been approved by FDA.

Primary Endpoints

Met on 08 Oct 2020

Time to recovery

description: Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Not hospitalized, no limitations on activities.
time_frame: Day 1 through Day 29 [1]

Other Endpoints

Change From Baseline in Alanine Transaminase (ALT)

description: Blood to evaluate ALT was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.
time_frame: Days 1, 3, 5, 8, 11, 15 and 29

Change From Baseline in Aspartate Transaminase (AST)

description: Blood to evaluate AST was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.
time_frame: Days 1, 3, 5, 8, 11, 15 and 29

Change From Baseline in Creatinine

description: Blood to evaluate serum creatinine was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.
time_frame: Days 1, 3, 5, 8, 11, 15 and 29

Change From Baseline in Glucose

description: Blood to evaluate serum glucose was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.
time_frame: Days 1, 3, 5, 8, 11, 15 and 29

Change From Baseline in Hemoglobin

description: Blood to evaluate hemoglobin was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.
time_frame: Days 1, 3, 5, 8, 11, 15 and 29

Change From Baseline in Platelets

description: Blood to evaluate platelets was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.
time_frame: Days 1, 3, 5, 8, 11, 15 and 29

Change From Baseline in Prothrombin Time (PT)

description: Blood to evaluate PT was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.
time_frame: Days 1, 3, 5, 8, 11, 15 and 29

Change From Baseline in Total Bilirubin

description: Blood to evaluate total bilirubin was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.
time_frame: Days 1, 3, 5, 8, 11, 15 and 29

Change From Baseline in White Blood Cell Count (WBC)

description: Blood to evaluate WBC was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.
time_frame: Days 1, 3, 5, 8, 11, 15 and 29

Change From Baseline in Neutrophils

description: Blood to evaluate neutrophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.
time_frame: Days 1, 3, 5, 8, 11, 15 and 29

Change From Baseline in Lymphocytes

description: Blood to evaluate lymphocytes was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.
time_frame: Days 1, 3, 5, 8, 11, 15 and 29

Change From Baseline in Monocytes

description: Blood to evaluate monocytes was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.
time_frame: Days 1, 3, 5, 8, 11, 15 and 29

Change From Baseline in Basophils

description: Blood to evaluate basophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.
time_frame: Days 1, 3, 5, 8, 11, 15 and 29

Change From Baseline in Eosinophils

description: Blood to evaluate eosinophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.
time_frame: Days 1, 3, 5, 8, 11, 15 and 29

Change in National Early Warning Score (NEWS) From Baseline

description: The NEW score has demonstrated an ability to discriminate patients at risk of poor outcomes. This score is based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness). The NEW Score is being used as an efficacy measure. The minimum score is 0, representing the better outcome, and the maximum value is 19, representing the worse outcome.
time_frame: Days 1, 3, 5, 8, 11, 15, 22, and 29

Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1

description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.
time_frame: Day 1

Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3

description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.
time_frame: Day 3

Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5

description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.
time_frame: Day 5

Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8

description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.
time_frame: Day 8

Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11

description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.
time_frame: Day 11

Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15

description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.
time_frame: Day 15

Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22

description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.
time_frame: Day 22

Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29

description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.
time_frame: Day 29

Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)

description: Grade 3 AEs are defined as events that interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating. Grade 4 AEs are defined as events that are potentially life threatening.
time_frame: Day 1 through Day 29

Percentage of Participants Reporting Serious Adverse Events (SAEs)

description: An SAE is defined as an AE or suspected adverse reaction is considered serious if, in the view of either the investigator or the sponsor, it results in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.
time_frame: Day 1 through Day 29

Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics

description: Participants may have been discontinued from investigational therapeutics due to discharge or death. The halting or slowing of the infusion for any reason was collected, as was missed doses in the series of 10 doses.
time_frame: Day 1 through Day 10

Duration of Hospitalization

description: Duration of hospitalization was determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die.
time_frame: Day 1 through Day 29

Duration of New Non-invasive Ventilation or High Flow Oxygen Use

description: Duration of new non-invasive ventilation or high flow oxygen use was measured in days among participants who were not on non-invasive ventilation or high-flow oxygen use at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die
time_frame: Day 1 through Day 29

Duration of New Oxygen Use

description: Duration of new oxygen use was measured in days among participants who were not on oxygen at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die
.
time_frame: Day 1 through Day 29

Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use

description: Duration of new ventilator or ECMO use was measured in days among participants who were not on a ventilator or ECMO at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die
time_frame: Day 1 through Day 29

Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use

description: New non-invasive ventilation or high-flow oxygen use was determined as the percentage of subject not on non-invasive ventilation or high-flow oxygen at baseline.
time_frame: Day 1 through Day 29

Percentage of Participants Requiring New Oxygen Use

description: The percentage of participants requiring new oxygen use was determined as the percentage of participants not requiring oxygen at baseline
time_frame: Day 1 through Day 29

Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use

description: The percentage of participants requiring new ventilator or ECMO use was determined as the percentage not on a ventilator or ECMO at baseline
time_frame: Day 1 through Day 29

Mean Change in the Ordinal Scale

description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. A positive change indicates a worsening and a negative change is an improvement.
time_frame: Day 1, 3, 5, 8, 11, 15, 22, and 29

14-day Participant Mortality

description: The mortality rate was determined as the proportion of participants who died by study Day 15.
time_frame: Day 1 through Day 15

29-day Participant Mortality

description: The mortality rate was determined as the proportion of participants who died by study Day 29.
time_frame: Day 1 through Day 29

Time to an Improvement by at Least One Category Using an Ordinal Scale

description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. Time to improvement by at least one category was determined for each participant
time_frame: Day 1 through Day 29

Time to an Improvement of at Least Two Categories Using an Ordinal Scale

description: The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities. Time to improvement by at least two categories was determined for each participant
time_frame: Day 1 through Day 29

Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First

description: The NEW score has demonstrated an ability to discriminate patients at risk of poor outcomes. This score is based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness). The NEW Score is being used as an efficacy measure. The minimum score is 0, representing the better outcome, and the maximum value is 19, representing the worse outcome. The time to discharge or a NEWS of less than or equal to 2 was determined for each participant.
time_frame: Day 1 through Day 29 [2]

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -

Subjects

  • Subject Type patients
  • Number

    Planned: 1032

    Actual: 1062

  • Sex male & female
  • Age Group 18-99 years (mean age -58.9 years); adult; elderly

Patient Inclusion Criteria

1. Admitted to a hospital with symptoms suggestive of COVID-19 infection. 2. Subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. 3. Subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 4. Male or non-pregnant female adult > / = 18 years of age at time of enrollment. 5. Has laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay in any specimen, as documented by either or the following: - PCR positive in sample collected < 72 hours prior to randomization; OR - PCR positive in sample collected >/= 72 hours prior to randomization, documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking >24 hours, etc.) AND progressive disease suggestive of ongoing SARS-CoV-2 infection. 6. Illness of any duration, and at least one of the following: - Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), OR - SpO2 < / = 94% on room air, OR - Requiring supplemental oxygen, OR - Requiring mechanical ventilation. 7. Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through Day 29. 8. Agrees to not participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 through Day 29.

Patient Exclusion Criteria

1. Alanine Transaminase (ALT) or Aspartate Transaminase (AST) > 5 times the upper limit of normal. 2. Estimated glomerular filtration rate (eGFR) < 30 ml/min (including patients receiving hemodialysis or hemofiltration). 3. Pregnancy or breast feeding. 4. Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours. 5. Allergy to any study medication.

Trial Details

Identifiers

Identifier Owner
NCT04280705 ClinicalTrials.gov: US National Institutes of Health
EudraCT2020-001052-18 European Clinical Trials Database
13035264 ISRCTN: Current Controlled Trials
U1111-1249-9599 World Health Organisation
20-0006 -
INSIGHTPROTOCOL010 -
010 -
20SC0154 -
DMID-Protocol-Number20-0006INSIGHT-Protocol-Number010UPHR - CPMS -

Organisations

  • Affiliations Gilead Sciences

Trial Dates

  • Initiation Dates

    Planned : 12 Mar 2020

    Actual : 21 Feb 2020

  • Primary Completion Dates

    Planned : 01 Apr 2023

    Actual : 21 May 2020

  • End Dates

    Planned : 01 Apr 2023

    Actual : 21 May 2020

Substudies/Extensions

Sub-study: Immune profiling reveals early disease trajectories associated with COVID-19 mortality

Other Details

  • Design double-blind; multicentre; open; parallel; prospective; randomised
  • Phase of Trial Phase III
  • Location Denmark; England; Germany; Greece; Italy; Japan; Mexico; Poland; Portugal; Singapore; South Korea; Spain; United Kingdom; USA
  • Focus Registrational; Therapeutic Use

Interventions

Drugs Route Formulation
BaricitinibPrimary Drug Oral Tablet
RemdesivirPrimary Drug Intravenous Infusion, Injection, Lyophilised

Placebo

200 mg of Remdesivir placebo administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir placebo while hospitalized for up to a 10 days total course. n=286. Other: Placebo (The supplied placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients. Alternatively, a placebo of normal saline of equal volume may be given if there are limitations on matching placebo supplies.)

Remdesivir

200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10 days total course. n=286. Drug: Remdesivir (Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.)

Results

Therapeutic efficacy

Final results from the phase III ACTT-1 trial showed that the primary endpoint was met with remdesivir plus standard of care demonstrating superiority in shortening the time to recovery through Day 29 compared with placebo plus standard of care. In the final Day 29 results, patients receiving remdesivir (n = 541) achieved clinical recovery five days faster than those receiving placebo, with a median time to recovery of 10 days with remdesivir and 15 days with placebo and an increased recovery rate by 29% compared with placebo (rate ratio for recovery, 1.29; 95% confidence interval [CI], 1.12 to 1.49; p<0.001). In patients who required oxygen support at baseline (n = 957)patients receiving remdesivir achieved clinical recovery seven days faster than those receiving placebo, with a median time to recovery of 11 days with remdesivir and 18 days with placebo (rate ratio for recovery, 1.31; 95% CI, 1.12 to 1.52). Patients receiving remdesivir demonstrated a 50% more likelihood to have improved by Day 15 compared with those receiving placebo (OR, 1.5; 95% CI, 1.2 to 1.9), and the effect was maintained through Day 29. Also, reduction in disease progression was observed in patients with oxygen requirement. This resulted in low incidence of new mechanical ventilation or ECMO (13% vs. 23%; 95% CI, -15 to -4). The benefit of remdesivir was found to be greater when given within 10 days of symptom onset. In the overall study population, a trend towards reduced mortality at Day 15 (6.7% vs. 11.9%; HR, 0.55; 95% CI, 0.36 to 0.83) and Day 29 (11.4% vs. 15.2%, HR 0.73; 95% CI, 0.52 to 1.03) was observed in remdesivir -treated patients compared with placebo [3] [1] . Earlier reported results from the trial demonstrated that administration of remdesivir statistically and significantly improved clinical odds at day 15 as compared to placebo group. The time for recovery as well as odds of improvement at day 15 were favourable for remdesivir group and consistent with overall study results. Earlier results demonstrated that patients treated with remdesivir recovered after about 10 days, compared with 15 days for patients given placebo. In patients with mild to moderate disease this effect was not observed, where time to recovery was 5 days for both the remdesivir group and the placebo group. Approximately 90% of the study population constituted patients with severe disease, where in time to recovery was 12 days in the remdesivir group and 18 days in the placebo group. However, no difference was observed in time to recovery in patients who started remdesivir when they were already on mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Data on the proportion of patients who died up to 28 days after starting treatment are currently being collected for final analysis. Initial preliminary results from the trial showed that treatment with remdesivir exhibited 31% of recovery from hospitalised patients (n = 1063) than those who received the placebo and suggested a survival benefit with mortality rate of 8.0% for the remdesivir group versus 11.6% for the placebo group [4] [5] .

Adverse events

In the phase III ACTT-1 trial, treatment with remdesivir was found to be generally safe and well tolerated. Overall, the incidence of adverse events associated with remdesivir was similar to placebo, with no new safety signals identified. Rates of serious adverse events (SAEs) were numerically higher in the placebo group compared with the remdesivir group (PBO + SOC: 32%; Veklury + SOC: 25%). Treatment discontinuation, all cause grade 3 and 4 adverse events and laboratory abnormalities were similar across groups [1] .

Publications

  1. Gilead Sciences. Final Results of National Institute of Allergy and Infectious Diseases ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury(Rm) (remdesivir) for the Treatment of COVID-19. Media-Rel 2020;.

    Media Release

  2. EvergreenHealth. EvergreenHealth Prepares for Second Arm of Clinical Trial After Initial Findings Show Promising Results for Remdesivir as Potential Treatment for COVID-19. Media-Rel 2020;.

    Media Release

  3. Paladugu S, Donato AA. Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement. . Ann-Intern-Med 2020;173(2):JC4.

    PubMed | CrossRef Fulltext

  4. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. . N-Engl-J-Med 2020;.

    PubMed | CrossRef Fulltext

  5. Thiede JM, Gress AR, Libby SD, Ronayne CE, Matchett WE, Noren B, et al. Immune profiling reveals early disease trajectories associated with COVID-19 mortality: a sub-study from the ACTT-1 trial. . J-Infect-Dis 2021;.

    PubMed | CrossRef Fulltext

Authors

Author Total Publications First Author Last Author
Atmar RL 1 - -
Babiker AG 1 - -
Beigel JH 1 1 -
Benfield T 1 - -
Billings JL 1 - -
Bold TD 1 - 1
Bonnett T 1 - -
Burgess TH 1 - -
Chu HY 1 - -
Creech CB 1 - -
Dierberg K 1 - -
Dodd LE 1 - -
Donato AA 1 - 1
EvergreenHealth 1 1 1
Fatkenheuer G 1 - -
Finberg RW 1 - -
Gilead Sciences 1 1 1
Green M 1 - -
Gress AR 1 - -
Hohmann E 1 - -
Hsieh L 1 - -
Kalil AC 1 - -
Kline S 2 - -
Kortepeter MG 1 - -
Lane HC 1 - 1
Langlois RA 1 - -
Libby SD 1 - -
Lopez de Castilla D 1 - -
Luetkemeyer A 1 - -
Lundgren J 1 - -
Lye DC 1 - -
Makowski M 1 - -
Matchett WE 1 - -
Mehta AK 1 - -
Menachery VD 1 - -
Nayak S 1 - -
Neaton JD 1 - -
Noren B 1 - -
Oh MD 1 - -
Ohmagari N 1 - -
Osinusi A 1 - -
Paladugu S 1 1 -
Paredes R 1 - -
Patterson TF 1 - -
Pett S 1 - -
Ronayne CE 1 - -
Ruiz-Palacios GM 1 - -
Short WR 1 - -
Sweeney DA 1 - -
Tapson V 1 - -
Thiede JM 1 1 -
Tomashek KM 1 - -
Touloumi G 1 - -
Zingman BS 1 - -

Trial Centres

Investigators

Download Data (CSV)
Investigator Centre Name Trial Centre Country
20-0006 Central Contact
13017617948 DMIDClinicalTrials@niaid.nih.gov
show details
-

Centres

Download Data (CSV)
Centre Name Location Trial Centre Country
-
-
-
AHEPA University Hospital - 1st Department of Internal Medicine Thessaloniki, Central Macedonia Greece
Atlanta VA Medical Center - Infectious Diseases Clinic Decatur, Georgia USA
Baylor College of Medicine - Molecular Virology and Microbiology Houston, Texas USA
Brooke Army Medical Center Fort Sam Houston, Texas USA
Cedars Sinai Medical Center West Hollywood, California USA
Changi General Hospital - Clinical Trials and Research Unit (CTRU) Singapore Singapore
Denver Health Division of Hospital Medicine - Main Campus Denver, Colorado USA
Duke Human Vaccine Institute - Duke Vaccine and Trials Unit Durham, North Carolina USA
Emory Vaccine Center - The Hope Clinic Decatur, Georgia USA
EvergreenHealth Infectious Disease Service Kirkland, Washington USA
Hospital Clinic Barcelona, Servicio de Salud Internacional Barcelona, Cataluña Spain
Hospital Germans Trias i Pujol - Servei Malalties Infeccioses Barcelona, Cataluña Spain
Hospital of the University of Pennsylvania - Infectious Diseases Philadelphia, Pennsylvania USA
Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia Mexico City Mexico
Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas Mexico City Mexico
John Radcliffe Hospital Headington, Oxford United-Kingdom
Johns Hopkins Hospital - Medicine - Infectious Diseases Baltimore, Maryland USA
Khoo Teck Puat Hospital - Clinical Research Unit Singapore Singapore
Madigan Army Medical Center - Infectious Disease Clinic Tacoma, Washington USA
Massachusetts General Hospital - Infectious Diseases Boston, Massachusetts USA
Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services Athens Greece
Montefiore Medical Center - Infectious Diseases Bronx, New York USA
National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center Tokyo Japan
National Centre for Infectious Diseases (NCID) Singapore Singapore
National Institute of Allergy and Infectious Diseases (NIAID)
-
-
National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section Bethesda, Maryland USA
National University Health System - Division of Infectious Diseases Singapore Singapore
Naval Medical Center Portsmouth - Infectious Disease Division Portsmouth, Virginia USA
Naval Medical Center San Diego - Infectious Disease Clinic San Diego, California USA
New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology New York, New York USA
Ng Teng Fong General Hospital - Infectious Disease Service Singapore Singapore
Northwestern Hospital - Infectious Disease Chicago, Illinois USA
Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases Hershey, Pennsylvania USA
Providence Sacred Heart Medical Center Spokane, Washington USA
Rocky Mountain Regional Veteran Affairs Medical Center - Department of Infectious Diseases Aurora, Colorado USA
Royal Sussex County Hospital - Department of Intensive Care Medicine East Sussex, Brighton United-Kingdom
Royal Victoria Infirmary - Department of Infectious Diseases Level 6, Ward 19, Newcastle Upon Tyne United-Kingdom
Saint Louis University - Center for Vaccine Development Saint Louis, Missouri USA
Saint Thomas' Hospital - Directorate of Infection London, London, City Of United-Kingdom
Seoul National University Bundang Hospital - Division of Infectious Diseases Bundang-gu Seongnam-si, Gyeonggi-do South-Korea
Seoul National University Hospital Seoul, Jongno-gu South-Korea
Singapore General Hospital - Department of Infectious Diseases Singapore Singapore
Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases New Orleans, Louisiana USA
St. James's University Hospital - Infectious Diseases Leeds, West Yorkshire United-Kingdom
Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases Palo Alto, California USA
The University of Washington - Virology Research Clinic Seattle, Washington USA
Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik Bonn, Nordrhein-Westfalen Germany
Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I Cologne Germany
University of Alabama at Birmingham School of Medicine - Infectious Disease Birmingham, Alabama USA
University of California Davis Medical Center - Internal Medicine - Infectious Disease Sacramento, California USA
University of California Irvine Medical Center - Infectious Disease Orange, California USA
University of California Los Angeles Medical Center - Westwood Clinic Los Angeles, California USA
University of California San Diego Health - Jacobs Medical Center La Jolla, California USA
University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine San Francisco, California USA
University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases Copenhagen Denmark
University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine Gainesville, Florida USA
University of Illinois at Chicago College of Medicine - Division of Infectious Diseases Chicago, Illinois USA
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore Annapolis, Maryland USA
University of Massachusetts Medical School - Infectious Diseases and Immunology Worcester, Massachusetts USA
University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine Minneapolis, Minnesota USA
University of Nebraska Medical Center - Infectious Diseases Omaha, Nebraska USA
University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology Philadelphia, Pennsylvania USA
University of Rochester Medical Center - Vaccine Research Unit Rochester, New York USA
University of Texas Health Science Center at San Antonio - Infectious Diseases San Antonio, Texas USA
University of Texas Medical Branch - Division of Infectious Disease Galveston, Texas USA
University of Virginia - Acute Care Surgery Charlottesville, Virginia USA
Universitätsklinikum Frankfurt -Medizinische Klinik II - Infektiologie Frankfurt Germany
VA Palo Alto Health Care System - Infectious Diseases Palo Alto, California USA
Vanderbilt University Medical Center - Infectious Diseases Nashville, Tennessee USA
Walter Reed National Military Medical Center Bethesda, Maryland USA

+ Lead Centre

Show all rows

Trial History

Event Date Event Type Comment
12 Jan 2021 Results Results (n=19) of a sub-study; serum specimens were obtained from hospitalized adults with COVID-19 randomized to Remdesivir or placebo from this trial assessing antibody and cytokine responses published in the Journal of Infectious Diseases Updated 01 Feb 2021
17 Dec 2020 Other trial event Last checked against European Clinical Trials Database record. Updated 17 Dec 2020
14 Dec 2020 Other trial event Last checked against ClinicalTrials.gov record. Updated 14 Dec 2020
23 Nov 2020 Other trial event According to a Montefiore Health System and Albert Einstein College of Medicine media release, Dr. Zingman was the principal investigator at Montefiore and Einstein for the ACTT-1 and ACTT-2 National Institutes of Health trials Updated 08 Dec 2020
22 Oct 2020 Results Additional mortality data from a post-hoc analysis were published in the New England Journal of Medicine, according to a Gilead Sciences media release. Updated 27 Oct 2020
22 Oct 2020 Other trial event According to a Gilead Sciences media release, the U.S. Food and Drug Administration (FDA) has approved Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization, based on data from ACTT-1 and SIMPLE-Severe studies. Updated 27 Oct 2020
08 Oct 2020 Endpoint met Primary endpoint (Time to recovery) has been met. Updated 14 Oct 2020
08 Oct 2020 Results Results published in Gilead Sciences Media Release. Updated 14 Oct 2020
08 Oct 2020 Other trial event According to a Gilead Sciences media release, the European Commission granted conditional marketing authorization of Veklury on July 3, 2020, based on data from this trial. Updated 13 Oct 2020
14 Sep 2020 Other trial event According to a Eli Lilly and Company media release, Andre Kalil, M.D., professor at the University of Nebraska Medical Center and a principal investigator of the ACTT studies. Updated 16 Sep 2020
31 Aug 2020 Other trial event Last checked against ISRCTN record. Updated 31 Aug 2020
28 Aug 2020 Other trial event According to a Gilead Sciences media release, based on the SIMPLE-moderate (Study GS-US-540-5774) and ACTT-1 studies, the USA Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) use of the investigational antiviral Veklury (remdesivir) to treat all hospitalized patients with COVID-19, in addition to the previous authorization for patients hospitalized with severe COVID-19. Updated 02 Sep 2020
10 Aug 2020 Other trial event According to an Gilead Sciences media release, it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Veklury (remdesivir), an investigational antiviral for the treatment of patients with COVID-19.The filing is supported by data from ACTT and SIMPLE Updated 12 Aug 2020
06 Aug 2020 Other trial event According to a National Institutes of Health media release, more detailed information about the results from this study, including more comprehensive data, will be available in a forthcoming report. Updated 17 Aug 2020
27 Jul 2020 Other trial event New source identified and integrated (ISRCTN: Current Controlled Trials :13035264 ). Updated 27 Jul 2020
14 Jul 2020 Other trial event According to a FHI Clinical Inc media release, the company announced that it has a subcontract with the Frederick National Laboratory for Cancer Research, currently operated by Leidos Biomedical Research, Inc., to provide clinical operations services for this study. Updated 16 Jul 2020
12 Jul 2020 Interim results Preliminary results assessing time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement treated with remdesivir, published in the Annals of Internal Medicine Updated 27 Jul 2020
07 Jul 2020 Status change - completed Status changed from recruiting to completed. Updated 09 Jul 2020
25 Jun 2020 Other trial event According to an European Medicines Agency media release, based on the data from this trial plus supporting data from other studies on remdesivir, EMA's human medicines committee (CHMP) has recommended granting a conditional marketing authorisation to Veklury (remdesivir) for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen. Updated 30 Jun 2020
24 Jun 2020 Other trial event Planned number of patients changed from 800 to 1032. Updated 24 Jun 2020
08 Jun 2020 Other trial event According to a European Medicines Agency media releas, EMA has received an application for conditional marketing authorisation of the remdesivir for the treatment of COVID-19 and has started its evaluation. The assessment of the benefits and risks of remdesivir is being performed under a reduced timeline and an opinion could be issued within weeks, depending on the robustness of the data submitted and whether further information is required to support the evaluation. Updated 15 Jun 2020
26 May 2020 Other trial event According to an Emmes media release, the company continues to support the adaptive-design of this study its second stage, in which subjects will be treated with remdesivir and randomized to receive the anti-inflammatory drug baricitinib. Updated 28 May 2020
22 May 2020 Interim results Interim Results published in the New England Journal of Medicine Updated 26 May 2020
18 May 2020 Other trial event According to an Enzychem Lifesciences media release, Dr. Cameron Wolfe is an investigator for this study. Updated 22 May 2020
11 May 2020 Other trial event According to an Emalex Biosciences media release, patients who receive a 5-day treatment course but do not show clinical improvement will be eligible to continue receiving remdesivir. Updated 18 May 2020
11 May 2020 Other trial event According to an Emalex Biosciences media release, a treatment duration of 5 days has been introduced alongside the longer 10-day course, based on preliminary results from another study (GS-US-540-5773) suggesting that for patients not requiring mechanical ventilation or ECMO, the treatment course may be shortened from 10 to 5 days without any loss of efficacy. Updated 18 May 2020
11 May 2020 Other trial event According to an Emalex Biosciences media release, although remdesivir is not yet authorised for marketing in the European Union, these recommendations for compassionate use will help some patients with severe COVID-19 access the medicine while EMA evaluates data on its benefits and risks. When the evaluation is complete, EMA will make a recommendation on whether or not remdesivir should receive a marketing authorisation. Updated 18 May 2020
11 May 2020 Other trial event According to an Emalex Biosciences media release, the updated recommendations are based on preliminary results from the NIAID-ACTT study, which suggest a beneficial effect of remdesivir in the treatment of hospitalised patients with severe COVID-19.EMA is currently evaluating these data in the context of the rolling review of remdesivir. Updated 18 May 2020
11 May 2020 Other trial event According to an Emalex Biosciences media release, in addition to patients undergoing invasive mechanical ventilation, the compassionate use recommendations now cover the treatment of hospitalised patients requiring supplemental oxygen, non-invasive ventilation, high-flow oxygen devices or ECMO (extracorporeal membrane oxygenation). Updated 18 May 2020
11 May 2020 Other trial event According to an Emalex Biosciences media release, EMAs human medicines committee (CHMP) has recommended expanding the compassionate use of the investigational medicine remdesivir so that more patients with severe COVID-19 can be treated. Updated 18 May 2020
07 May 2020 Other trial event According to an Gilead Sciences media release, the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Veklury (remdesivir) as a treatment for SARS-CoV-2 infection under an exceptional approval pathway. The exceptional approval was granted due to the COVID-19 pandemic and references the Emergency Use Authorization of remdesivir in the United States. Updated 12 May 2020
07 May 2020 Other trial event According to an Gilead Sciences media release, the Japanese Ministry of Health, Labour and Welfare (MHLW) approval is based on clinical data from the U.S. National Institute of Allergy and Infectious Diseases's global Phase 3 trial, the company's Phase 3 SIMPLE trial in patients with severe manifestations of COVID-19, and available data from company's compassionate use program, including patients in Japan. Updated 12 May 2020
04 May 2020 Other trial event According to an Gilead Sciences media release, data from this study will be reviewed by CHMP as a part of rolling review. Updated 06 May 2020
01 May 2020 Other trial event According to a Gilead Sciences media release, the EUA is based on available data from two global clinical trials, the National Institute for Allergy and Infectious Diseases placebo-controlled Phase 3 study in patients with moderate to severe symptoms of COVID-19 (NCT04280705), including those who were critically ill, and Gileads global Phase 3 study evaluating 5-day and 10-day dosing durations of remdesivir in patients with severe disease (NCT04292899). Updated 08 May 2020
01 May 2020 Other trial event According to a Gilead Sciences media release, the EUA is temporary and does not take the place of the formal new drug application submission, review and approval process. The EUA allows for the distribution and emergency use of remdesivir only for the treatment of COVID-19, remdesivir remains an investigational drug and has not been approved by FDA. Updated 08 May 2020
01 May 2020 Other trial event According to a Gilead Sciences media release, the U.S. FDA has granted emergency use authorization (EUA) for the investigational antiviral remdesivir to treat COVID-19. The EUA will facilitate broader use of remdesivir to treat hospitalized patients with severe COVID-19 disease, enabling access to remdesivir at additional hospitals across the country. Under the EUA, both 5-day and 10-day treatment durations are suggested, based on the severity of disease. Updated 08 May 2020
30 Apr 2020 Other trial event According to an EvergreenHealth media release, Dr. Diego Lopez de Castilla, EvergreenHealth infectious disease specialist is a lead investigator of the study. Updated 05 May 2020
30 Apr 2020 Results Results (n=1063) presented in an EvergreenHealth media release. Updated 05 May 2020
30 Apr 2020 Other trial event According to an EvergreenHealth media release, the institute is preparing to move forward the study by entering into the second arm of the study. The second phase of the trial, ACTT II, will eliminate the placebo group, and instead provide all study participants with Remdesivir. All the patients from the EvergreenHealth's care will receive an open-label Remdesivir. The ACTT II is expected to run for three years. Updated 05 May 2020
29 Apr 2020 Other trial event According to an Gilead Sciences media release, NIAID will provide detailed information at an upcoming briefing Updated 07 May 2020
29 Apr 2020 Endpoint met Primary endpoint has been met. (Time to recovery) Updated 07 May 2020
23 Apr 2020 Other trial event Planned number of patients changed from 572 to 800. Updated 29 Apr 2020
16 Apr 2020 Protocol amendment Primary endpoint has been changed from "Percentage of subjects reporting each severity rating on an 8-point ordinal scale" to Time to recovery. Updated 21 Apr 2020
16 Apr 2020 Other trial event Planned number of patients changed from 440 to 572. Updated 21 Apr 2020
10 Apr 2020 Other trial event According to an Gilead Sciences media release, this study continues to enroll patients and data are anticipated in May 2020. Updated 16 Apr 2020
30 Mar 2020 Other trial event New source identified and integrated:European Clinical Trials Database;EudraCT2020-001052-18. Updated 30 Mar 2020
24 Mar 2020 Other trial event According to an UC San Dieg media release,The trial is projected to run to April 1, 2023 and will ultimately involve an estimated total of 440 participants. It is sponsored by the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health (NIH). Updated 07 May 2020
24 Mar 2020 Other trial event According to an UC San Dieg media release, Constance Benson, M.D., professor of medicine at UC San Diego School of Medicine and an infectious disease specialist at UC San Diego Health.o health media release is co-principal investigator of this study and this study sponsored by the National Institute of Allergy and Infectious Disease, part of the National Institutes of Health (NIH). Updated 07 May 2020
21 Mar 2020 Other trial event According to a U.S. Department of Health and Human Services media release, the US Department of Health and Human Services id funding this trial. Updated 26 Mar 2020
20 Mar 2020 Protocol amendment Phase has been changed from phase II to phase III. Updated 26 Mar 2020
20 Mar 2020 Other trial event Planned number of patients changed from 394 to 440. Updated 26 Mar 2020
25 Feb 2020 Other trial event According to a National Institute of Allergy and Infectious Diseases media release, the first participant is an American who was repatriated after being quarantined on the Diamond Princess cruise ship that docked in Yokohama, Japan and volunteered to participate in the study. Updated 27 Feb 2020
25 Feb 2020 Status change - recruiting Status changed from not yet recruiting to recruiting, according to a National Institute of Allergy and Infectious Diseases media release. Updated 27 Feb 2020
24 Feb 2020 New trial record New trial record Updated 24 Feb 2020

References

  1. Gilead Sciences. Final Results of National Institute of Allergy and Infectious Diseases ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury(Rm) (remdesivir) for the Treatment of COVID-19. Media-Rel 2020;.

    Media Release

  2. ClinicalTrials.gov: US National Institutes of Health. Trial-Reg 2016;.

    Available from: URL: http://clinicaltrials.gov

  3. Gilead Sciences. U.S. Food and Drug Administration Approves Gileads Antiviral Veklury(Rm) (remdesivir) for Treatment of COVID-19. Media-Rel 2020;.

    Media Release

  4. European Medicines Agency. First COVID-19 treatment recommended for EU authorisation . Media-Rel 2020;.

    Media Release

  5. EvergreenHealth. EvergreenHealth Prepares for Second Arm of Clinical Trial After Initial Findings Show Promising Results for Remdesivir as Potential Treatment for COVID-19. Media-Rel 2020;.

    Media Release

  6. US Department of Health and Human Services. HHS Funds Phase 2/3 Clinical Trial for Potential Treatment for COVID-19. Media-Rel 2020;.

    Media Release

  7. New COVID-19 Vaccine Unit Opens at Montefiore and Albert Einstein College of Medicine. Media-Rel 2020;.

    Media Release

  8. ISRCTN: Current Controlled Trials. Trial-Reg 2016;.

    Available from: URL: http://www.controlled-trials.com

  9. Gilead Sciences. Gileads Investigational Antiviral Remdesivir Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of COVID-19. Media-Rel 2020;.

    Media Release

  10. UC San Diego Health Launches Clinical Trial to Assess Antiviral Drug for COVID-19. Media-Rel 2020;.

    Media Release

  11. European Clinical Trials Database. Trial-Reg 2016;.

    Available from: URL: https://www.clinicaltrialsregister.eu

  12. Eli Lilly and Company. Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial. Media-Rel 2020;.

    Media Release

  13. Gilead Sciences. Gilead Sciences Signs Joint Procurement Agreement With the European Commission for Veklury(RM)(remdesivir). Media-Rel 2020;.

    Media Release

  14. Gilead Sciences. Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury(Rm) (Remdesivir) for the Treatment of COVID-19. Media-Rel 2020;.

    Media Release

  15. National Institutes of Health. NIH clinical trial testing remdesivir plus interferon beta-1a for COVID-19 treatment begins. Media-Rel 2020;.

    Media Release

  16. Gilead Sciences. Gileads Investigational Antiviral Veklury(R)(Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19. Media-Rel 2020;.

    Media Release

  17. Paladugu S, Donato AA. Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement. . Ann-Intern-Med 2020;173(2):JC4.

    PubMed | CrossRef Fulltext

  18. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. . N-Engl-J-Med 2020;.

    PubMed | CrossRef Fulltext

  19. European Medicines Agency. EMA starts rolling review of remdesivir for COVID-19. Media-Rel 2020;.

    Media Release

  20. Emalex Biosciences. EMA recommends expanding remdesivir compassionate use to patients not on mechanical ventilation. Media-Rel 2020;.

    Media Release

  21. FHI Clinical. FHI Clinical Inc. Providing Clinical Operations Services for ACTT-1 Trial of Remdesivir for Treatment of COVID-19. Media-Rel 2020;.

    Media Release

  22. National Institute of Allergy and Infectious Diseases. NIH Clinical Trial of Remdesivir to Treat COVID-19 Begins. Media-Rel 2020;.

    Media Release

  23. Gilead Sciences. Gilead Announces Approval of Veklury(Rm) (remdesivir) in Japan for Patients With Severe COVID-19. Media-Rel 2020;.

    Media Release

  24. Thiede JM, Gress AR, Libby SD, Ronayne CE, Matchett WE, Noren B, et al. Immune profiling reveals early disease trajectories associated with COVID-19 mortality: a sub-study from the ACTT-1 trial. . J-Infect-Dis 2021;.

    PubMed | CrossRef Fulltext

  25. Enzychem Lifesciences Corporation. Enzychem Lifesciences Appoints Duke Medical Coronavirus Task Force Expert Dr. Cameron Wolfe to Lead Development of EC-18 as a COVID-19 Therapeutic Drug. Media-Rel 2020;.

    Media Release

  26. European Medicines Agency. EMA receives application for conditional authorisation of first COVID-19 treatment in the EU. Media-Rel 2020;.

    Media Release

  27. Gilead Sciences. Data on 53 Patients Treated With Investigational Antiviral Remdesivir Through the Compassionate Use Program Published in New England Journal of Medicine. Media-Rel 2020;.

    Media Release

  28. Emmes Announces its Contribution to NIH ACTT Clinical Trial for Remdesivir. Media-Rel 2020;.

    Media Release

  29. Gilead Sciences. Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases Study of Investigational Antiviral Remdesivir for COVID-19. Media-Rel 2020;.

    Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG

Legal

Back to top